Here are three things to know from the study:
- TESI could provide a therapeutic alternative to the current standard treatment of SBS, solving challenges such as donor shortages in regard to transplants of the intestine as well as immunosupression.
- Researchers previously demonstrated TESI replicates key components of native intestine.
- The new study shows TESI holds a “well-differentiated epithelium with intact ion transporters/channels, functional brush-border enzymes and similar ultrastructural components to native tissue, including progenitor cells, whether derived from mouse or human cells.”
You can view the study abstract here.
More articles on GI/endoscopy:
Gastroenterology special issue: “You are what you eat”
Boston Scientific sales hit $1.77 billion in Q1: 5 things to know
GI physician leader to know: Dr. Lawrence Kosinski of Illinois Gastroenterology Group
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.